Volume 99
Published on March 2025Volume title: Proceedings of the 5th International Conference on Biological Engineering and Medical Science
Catechol is a pollutant commonly found in industrial and everyday wastewater, with genotoxic effects that can lead to mutations, DNA fragmentation, and chromosomal aberrations. Traditional physical and chemical degradation methods face challenges such as high costs and secondary pollution, whereas biological degradation offers a cost-effective and environmentally friendly alternative. This study investigates the use of the Bacillus subtilis spore surface display system for catechol degradation, aiming to develop an efficient, low-cost biodegradation method. Recombinant Bacillus subtilis was successfully engineered to display catechol 1,2-dioxygenase (C12O) and catechol 2,3-dioxygenase (C23O) on the spore surface. Immunoblotting and immunofluorescence confirmed protein display and enzyme activity assays demonstrated catechol degradation activity. The displayed enzymes showed stability across a wide pH and temperature range, maintaining activity even under methanol conditions. Compared to purified proteins, the spore-bound enzymes eliminated purification steps, reducing costs and improving degradation efficiency in some conditions. These results suggest that the Bacillus subtilis spore display system has great potential in biocatalysis, offering a novel strategy for environmental pollution remediation.
View pdf
Chronic myelogenous leukemia (CML) and non-small cell lung cancer (NSCLC) are two common malignant tumors. Traditional treatments mainly include chemotherapy, radiotherapy, and bone marrow transplantation for CML. However, the low success rate of donor matching limits the widespread use of bone marrow transplants. The development of tumors is closely related to mutations or overexpression of multiple oncogenes, but their regulatory mechanisms and effective therapeutic strategies are still unclear. In recent years, the rapid development of gene editing technology, especially the CRISPR-Cas9 system, has provided new technical means for screening therapeutic targets for leukemia and lung cancer. This project utilizes the CRISPR-Cas9 system to knock out the MYC gene, which is considered a key oncogene in many human cancers. The first step of this project is to construct MYC gene knockout cell lines for CML and NSCLC, and to evaluate the effects on tumor cell proliferation and differentiation in vitro. It is expected that knocking out the MYC gene will significantly inhibit tumor cell proliferation and activate the expression of differentiation-related genes. This study will help reveal the role of the MYC gene in tumorigenesis and provide important theoretical support and potential clinical application value for targeted therapy of CML and NSCLC, further promoting the development of personalized precision medicine.
View pdf